HR and breast cancer: Within HR+/HER2-neg BC, the HER2-enriched subtype is found in 6%–20% of cases (21, 22) and does not differ much from that within clinical HER2-positive BC from a gene expression perspective, except for a lack of ERBB2 overexpression and amplification (38).